Wednesday, July 05, 2017 8:20:31 AM
The doctors say as much as they can right up to the cystoscope question.
Phase 2 is the critical (no phase 3 required)
3/10 for drug approval for 'response rate'
The odds are heavily stacked in our favour.. I mean lol.. I expect the low dose to give us 3/3 alone.
When Dr.Jewett talked about the previous trial vs this one..... easy to see in 2017 where the technology has advanced to with micro-calculations and mini equipment to do things we couldn't do in 1998
*salute*
Just hope we can boost the pps before the next fundraise
Love stocks that have; Revenues, No Toxic Debts & Innovative project ambitions.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM